



Introducing GlobalData

BizInt eLearning Webinar

Revati Tatake, PhD
Global Director of Databases and Analytics
Pharma Intelligence Center

April 7, 2021

OVERVIEW

We are a leading provider of data, insights, and analytics for the world's largest industries

MISSION

To help our clients decode the future, make better decisions, and reach more customers

PROPOSITION

- Unique Data
- Expert Analysis
- Innovative Solutions
- One Platform

INDUSTRY COVERAGE – WITH A “TRIPLE PLAY” IN HEALTHCARE



Aerospace, Defence
& Security



Apparel



Automotive



Banking & Payments



Construction



Consumer



Foodservice



Healthcare



Insurance



Medical



Mining



Oil & Gas



Packaging



Pharmaceutical



Power



Retail



Technology



Travel & Tourism



GlobalData's Pharma Intelligence Center

Who we are and what we do?

- GlobalData's Pharma Intelligence Center combines in-depth analysis, exclusive news, the most comprehensive data and granular market intelligence to provide a complete 360° view into the Pharmaceutical Industry.

LEADING FULLY-INTEGRATED ONLINE PLATFORM

- Combines analytical reports, databases and workflow tools
- Strong in-tool analytical capabilities
- Automated alerts to embed into our clients' workflows
- Single login

SPECIALITY DISEASE EXPERTS


In-depth forecast and analysis for highly prevalent and emerging, rare and niche diseases

TRANSPARENT METHODOLOGIES

- All assumptions and data sources are captured in reports and databases
- Full access to market forecast calculations, including: epidemiology data, segmentations, patient shares, costs of therapy and compliance rates, provided in a supporting Excel deliverable

COMMERCIAL EPIDEMIOLOGY

Patient-based forecasting model to determine the market size for therapeutic indications.



DELIVERED THROUGH
ONE SINGLE PLATFORM




- **Pharma Intelligence Center** offers complete solution for market and competitive intelligence based on historical events and future catalysts for drug development, manufacturing, clinical trials, likelihood of drug approvals, drug sales forecast and much more...



- *BizInt export option is now available for Clinical Trials and Drugs Databases!*

Pharma Intelligence Center: Our interactive and fully-integrated platform



How to create BizInt charts from GlobalData?



Support: Creating Reports from Databases/Hosts

Creating from GlobalData


Version 5.3 of the BizInt Smart Charts Drug Development Suite introduces support for drugs and trials on GlobalData.

Version 5.3 is planned for release on 28 March 2021.

Note: at present, the export is limited to 1000 drugs or trials. If you need to export more, construct searches to build subsets of the results, export those, and then combine in BizInt Smart Charts. If your subsets overlap, BizInt will automatically remove the duplicates.

Step by Step

1. Conduct your search.
2. On the results page, click on the Export item to open the Export menu.
3. Choose the "BizInt Smart Charts" format.



4. Depending on how your computer is configured, BizInt Smart Charts may launch automatically. If it does not, you will see a dialog from your browser asking what you want to do with the file. You may save this file, to import at a later time, or open the file directly.

Conduct your search

Drugs Database

Drug Search

Search Type Hide all Make Selections Confirm your Search

Companies +

Drugs -

Drug Name

Therapy Area/Indication

Development Stage

Route of Administration

Molecule Type

Drug Geography

Target

Mechanism of Action

ATC Classification

Drug Type

Drug Type

Biosimilar

Generic

> Innovator

Note: "NME/Non-NME" is only applicable for Marketed Drugs

Therapy Area

Infectious Disease x

Indication

Coronavirus Disease 2019 (COVID-19) x

Drug Type

Innovator x

Drug Descriptor

Prophylactic Vaccine x

Search Clear Search

Search Results

Drugs - Results

Refine Drugs Save Search

Your Refinements Therapy Area Infectious Disease Indication Coronavirus Disease 2019 (COVID-19) Drug Descriptor Prophylactic Vaccine

Note: Click on Integrated Results to get a further breakdown of your results by Drug Type, Sales forecasts, Drugs by Manufacturer, Clinical Trials

1 - 10 of 473 Drugs | Results Analytics + Customize Tables Export Integrated Results My Custom Downloads Page 1 of 48 Previous Next

Drug Name	Generic Name	Company Name	Therapy Area	Indication
Coronavirus Disease 2019 (COVID-19) (whole virion) vaccine		Federal Research Center for Research and Development of Immunobiological Preparations	Infectious Disease	Coronavirus Disease 2019 (COVID-19)
Coronavirus Disease 2019 (COVID-19) Vaccine		Gamaleya Federal Research Center of Epidemiology and Microbiology	Infectious Disease	Coronavirus Disease 2019 (COVID-19)
	Sputnik V		Infectious Disease	

Select BizInt Smart Charts from multiple export options

From BizInt export for drugs, you can connect to individual drug for additional information



Preview

Key Attributes

Marketed Information

Pipeline Information

Partnering Details

R&D

Regulatory Milestones

Sales and Forecast

Likelihood of Approval (LoA)

Competing Drugs

Manufacturing

Clinical Trials

Catalyst Events

Insights

Updates Overview

Net Present Value (NPV)

Deals

News

History of Changes

Export ▼

Track It

Ask the Expert

>

Drug Name
pembrolizumab

◎

Generic Name
pembrolizumab

⌘

Brand Name
Keytruda

☰

Company Name
Merck & Co Inc

Sales and Forecast

Patient Based Forecasts are only for indications present in the Therapy Reports

Likelihood of Approval (LoA)

Therapy Area	Indication	Development Stage	PTSR	LoA
Oncology	Malignant Pleural Mesothelioma	Phase III	44%	37%
Oncology	Muscle Invasive Bladder Cancer (MIBC)	Phase III	16%	10%
Oncology	Oral Cavity (Mouth) Cancer	Phase III		24%
Oncology	Urethral Cancer			
Oncology	Ureter Cancer			
Oncology	Peritoneal Cancer			

Clinical Trials

Planned - 56

Ongoing - 509 Completed - 122

294

Insights

Drug Insights - 285

Outsourcing - 66

142

Deals

Partnership - 94 Acquisition - 1

Equity Offerings - 2

453

News

Clinical Trials - 220

Regulatory - 137

Product Development - 407

Catalyst Calendar

Catalysts by Year				
2021	2022	2023	2024	2025
290	211	123	68	44
2025	2026	2027	2028	2029
44	25	8	8	8
2030	2031	2032	2033	2034
8	1	3	5	5

Analyst consensus and GlobalData's proprietary patient based drug sales forecasts

Integrated data with direct links to datasets

Phase Transition Success Rate and Likelihood of Approval for pipeline indications

Upcoming Catalysis

Easy to navigate menu to find information you are looking for

From BizInt export for trials, you can connect to individual trial records on Pharma Intelligence Center



- Clinical Trial Overview
- Clinical Trial Details
- Sponsor(s)/Collaborator(s)
- Drug Details
- Patient Details
- Biomarker Details
- Trial Results
- Enrollment Data
- Investigator(s)
- Location(s)
- Contact Detail(s)
- Site Coordinator Detail(s)
- Key Trial Events
- Insights
- Sources
- History of changes

Clinical Trial:

A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants with Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)

Export Track it Ask the Expert

Page 16 of 752 | Previous Next | Go to page >

<p>Trial Title A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants with Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)</p>	<p>Trial Identifier GDCT0224252</p>	<p>Secondary Ids EudraCT-2014-002009-40 ; MK-3475-045; NCT02256436; 3475-045; CDR765218; NCI-2014-02598; JapicCTI-152903; DRKS00008947; 152903; Study KN045; Study PNO45; Study KN-045; 201400553; 2014-002009-40;</p>	<p>Sponsor Merck & Co Inc</p>
<p>Indication Bladder Cancer, Malignant Neoplasms, Metastatic Transitional (Urothelial) Tract Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Ureter Cancer, Urethral Cancer</p>	<p>Trial Status Completed</p>	<p>Trial Phase Phase III</p>	<p>Approved Health Authority Austria: Austrian Federal Office for Safety in Health Care (BASG); Belgium: Federal Public Service (FPS) Health - Directorate-General Medicines (DGM); Denmark: Danish Health and Medicines Authority (DHMA); Hungary: National Institute of Pharmacy (NIP); Portugal: National Authority of Medicines and Health Products (INFARMED); Spain: Spanish Agency of Medicines and Medical Devices (AEMPS); Sweden: Medical Products Agency (MPA); United Kingdom: Medicines and Healthcare products Regulatory Agency (MHRA); Germany: Paul-Ehrlich-Institut (PEI); The Netherlands: Netherlands Competent Authority; Ireland: The Health Products Regulatory Authority (HPRA); Poland: Office for Medicinal Products</p>
<p>Data Monitoring Committee YES</p>	<p>Drug(s)/Molecule pembrolizumab</p>	<p>Secondary Intervention vinflunine ditartrate; paclitaxel; docetaxel</p>	

Easy to navigate menu to find information you are looking for

Full trial details

Basic trial information

Last Reviewed on 12 Feb 2021

Clinical Trial Details

Trial Title	A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants with Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045)
Official Title	A Phase III Randomized Clinical Trial of Pembrolizumab (Mk-3475) Versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer
Acronym	KEYNOTE-045
Study Type	Interventional

For More Information and Demo - Contact us at www.globaldata.com



Report Store

Media

Investors

Careers

Consulting

Contact Us

Request a Demo

Client Login



Who We Are

Industries We Cover

Who We Serve

03 **Decode the future**

In an increasingly complex, uncertain, and fast-moving world, our mission is to help you decode the future to be more successful and innovative...

[Find out more](#)

- CEO Response to Coronavirus
- Decode The Future
- Decades of Experience
- An Insightful Approach
- Trusted By Many